Analysts have been eager to weigh in on the Healthcare sector with new ratings on Harmony Biosciences Holdings (HRMY – Research Report) and Astria Therapeutics (ATXS – Research Report).
Harmony Biosciences Holdings (HRMY)
In a report released today, Corinne Johnson from Goldman Sachs reiterated a Sell rating on Harmony Biosciences Holdings. The company’s shares closed last Monday at $32.95.
According to TipRanks.com, Johnson is a 4-star analyst with an average return of
Currently, the analyst consensus on Harmony Biosciences Holdings is a Hold with an average price target of $38.50.
See the top stocks recommended by analysts >>
Astria Therapeutics (ATXS)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Astria Therapeutics today and set a price target of $18.00. The company’s shares closed last Monday at $14.94, close to its 52-week high of $16.80.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Astria Therapeutics with a $21.33 average price target, a 27.3% upside from current levels. In a report issued on March 11, LifeSci Capital also maintained a Buy rating on the stock with a $18.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HRMY:
- Harmony Biosciences price target lowered to $40 from $42 at Mizuho
- Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Harmony Biosciences Releases Investor Presentation Update
- Harmony Biosciences reports Q4 adjusted EPS 73c, consensus 48c
- Harmony Biosciences: FDA grants priority review for sNDA for WAKIX
